2025
Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes
How J, Leiva O, Redd R, Marneth A, DeAngelo D, Dieli-Conwright C, El-Jawahri A, Kamaz B, Kim C, Lindsley C, Luskin M, Stahl M, Wazir M, Weeks L, Hobbs G. Cardiovascular Risk Factors in Myeloproliferative Neoplasms: Associations with Survival and Thrombotic Outcomes. Blood Vessels Thrombosis & Hemostasis 2025, 100051. DOI: 10.1016/j.bvth.2025.100051.Peer-Reviewed Original ResearchMyeloproliferative neoplasm patientsCardiovascular risk factorsEssential thrombocythemiaMyeloproliferative neoplasmsPolycythemia veraThrombotic outcomesThrombotic riskRisk factorsDiagnosis of hematological malignanciesMyeloproliferative neoplasm subtypeIncreased risk of deathType 2 diabetes mellitusMyeloproliferative neoplasms diagnosisRetrospective cohort analysisSex-matched controlsManaging cardiovascular risk factorsAssociated with survivalImprove patient morbidityRisk of deathMF patientsHematologic malignanciesMPN diagnosisPatient morbidityDana-FarberArterial/venous thrombosis
2023
Unlike TET2 and ASXL1, Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2-Mutant Myeloproliferative Neoplasms (MPNs)
How J, Marneth A, Kamaz B, Kim C, Neuberg D, Ren S, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hormoz S, Mullally A. Unlike TET2 and ASXL1, Co-Occurring DNMT3A Mutations Are Not Associated with Increased Age in JAK2-Mutant Myeloproliferative Neoplasms (MPNs). Blood 2023, 142: 4521. DOI: 10.1182/blood-2023-179407.Peer-Reviewed Original ResearchJAK2-mutated myeloproliferative neoplasmsJAK2-mutated patientsFraction of patientsVariant allele fractionASXL1 mutationsDNMT3A mutationsMyeloproliferative neoplasmsConcomitant mutationsMyeloproliferative neoplasms diagnosisAssociated with increasing ageEssential thrombocythemiaPolycythemia veraDriver mutationsMyeloproliferative neoplasm driver mutationsNext generation sequencingCo-mutated patientsHomozygous JAK2 mutationPhenotypic driver mutationsClinical next generation sequencingJAK2-mutantMPL mutationsMF patientsClonal hematopoiesisPV patientsJAK2 mutationCardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes
How J, Leiva O, Marneth A, Kamaz B, Kim C, Weeks L, Wazir M, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G. Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes. Blood 2023, 142: 4568. DOI: 10.1182/blood-2023-179324.Peer-Reviewed Original ResearchMyeloproliferative neoplasm patientsEssential thrombocythemiaVariant allele fractionMyeloproliferative neoplasmsPolycythemia veraAcute myeloid leukemiaHistory of atherosclerotic diseaseMF patientsCV-RFCardiovascular risk factorsRisk of deathOverall survivalRisk factorsMPN diagnosisLeukemia progressionArterial thrombosisGenomic profilingHazard ratioAssociated with increased risk of deathAssociated with adverse outcomesAssociated with higher risk of deathAtherosclerotic diseaseAssociated with increased riskHigher risk of deathAssociated with higher risk
2020
Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis
Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma & Leukemia 2020, 20: e712-e723. PMID: 32669244, PMCID: PMC7541411, DOI: 10.1016/j.clml.2020.05.018.Peer-Reviewed Original ResearchConceptsOverall response rateTreatment of myelofibrosisPEG-IFNMF patientsResponse rateHematologic responseSystematic reviewFormulations of interferonPartial hematologic responseCochrane Central RegisterComplete hematologic responseRisk of progressionRole of interferonAcute myeloid leukemiaPhiladelphia chromosome-negative myeloproliferative neoplasmsRandom-effects modelBone marrow failureWeb of ScienceTreatment discontinuationCentral RegisterConstitutional symptomsHematologic improvementInterferon therapyAdverse eventsComplete response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply